ClinicalTrials.govpublic full text
Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor Q702 in Combination With Pembrolizumab in Patients With Selected Advanced Solid Tumors
esophageal cancer, gastric cancer, hepatocellular cancer, cervical cancer, interventional, phase1, phase2
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Related documents
Record · ID 895281
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.